Stock futures kicked off the overnight session roughly flat after volatile trading day Thursday, with stocks whipsawed amid conflicting signals over coronavirus clinical trial results
Stock futures kicked off the overnight session roughly flat on the heels of a volatile trading day Thursday, with stocks whipsawed amid conflicting signals over the results of a clinical trial for a coronavirus antiviral treatment candidate.
The Financial Times cited draft documents accidentally published by the World Health Organization in reporting that a Chinese study for Gilead’s drug remdesivir produced inconclusive results in the treatment’s first randomized clinical trial – a characterization which Gilead later disputed.
The coronavirus pandemic showed further, but still tentative, signs of levelling off on Thursday, with hospitalizations and new diagnoses declining in the hardest-hit U.S. states of New York and New Jersey. Separately, however, California reported its “deadliest day” on Thursday, adding 115 new deaths, or the highest for the state in a 24-hour period.
Earlier this week, some southern states began a multi-phase economic reopening process. However, many medical experts have warned that easing social distancing restrictions across the country too soon could backfire and trigger another major wave of infections.
Still, weeks-long social distancing measures have ravaged the U.S. economy. Further signs of the devastating economic toll from the coronavirus pandemic emerged on Thursday, with the Labor Department reporting another 4.427 million individuals filed new unemployment claims last week. The new data marked the third straight week that new jobless claims fell on a week-over-week basis, but brought the total number of initial unemployment insurance claims over the last five weeks to more than 26 million.
Net, net, jobless claims are warning that the worst isn’t over yet for the American economy with businesses and consumers alike being sucked down into the abyss of the pandemic recession, Chris Rupkey, chief financial economist for MUFG, wrote in a note Thursday.
Thursday after market close, the U.S. House of Representatives passed a $486 billion relief package to provide funds to small businesses and hospitals upended by the pandemic. The legislation, which boosts a vital small business aid program that ran out of funds last week, was cleared by the Senate earlier this week, and heads to President Donald Trump’s desk for signing.
This article is for information purposes only.
Please remember that financial investments may rise or fall and past performance does not guarantee future performance in respect of income or capital growth; you may not get back the amount you invested.
There is no obligation to purchase anything but, if you decide to do so, you are strongly advised to consult a professional adviser before making any investment decisions.